WELL Health Technologies Corp. (WELL) Earnings Call Transcript
November 9, 2026
Earnings Call Speaker Segments
Thank you, operator, and welcome everyone to the conference call covering WELL Health's financial results for the fiscal third quarter, for the period that ended September 30th, 2026. I hope everyone has received a copy of the press release on our financial results that was issued earlier today. Certain portions of today's call, apart from historical performance, contain statements of forward-looking information as defined under applicable securities laws, including future-oriented financial information as well as financial outlook information. These forward-looking statements come with risks—both known and unknown—along with uncertainties, assumptions, and other factors, and a good many of them sit beyond WELL's ability to control. Any of these could make WELL's real results, performance, or achievements diverge substantially from what those statements anticipate or imply. You can find a fuller description of these factors in today's press release as well as in our management's discussion and analysis. Our forward-looking statements exist only to inform you about what management currently anticipates and plans for the future. We make no commitment—and take on no duty—to publicly issue updates or revisions to any forward-looking statement, whether to reflect a shift in our expectations or a shift in the events, conditions, assumptions, or circumstances underlying such a statement, unless the law demands it. During this call, we might reference certain terms—adjusted gross profit, adjusted gross margin, adjusted EBITDA, adjusted EBITDA margin, adjusted EBITDA attributable to shareholders, adjusted net income, adjusted free cash flow, and adjusted free cash flow attributable to shareholders—each of which is a non-GAAP and non-IFRS measure; details on our definitions for these terms appear in the definitions section of today's press release as well as in our management's discussion and analysis. Management considers adjusted EBITDA a meaningful financial metric because it captures cash produced by operations, which the company can deploy toward working capital needs, paying future interest and principal on debt, and supporting future growth initiatives. Adjusted EBITDA isn't meant to be viewed as a substitute for net income or loss calculated under IFRS. Joining us on today's call, we have Chairman and CEO Hamed Shahbazi, along with Evelyn Sutherland, the company's CFO. With that said, I'll now hand the call over to Hamed Shahbazi, WELL Health Technologies' Chairman and CEO.
Thank you, Pardeep, and good day to all of you. We're grateful that you could join us. Before we discuss the quarter, I want to pause and extend a very warm welcome to Evelyn Sutherland, who came aboard at WELL as our Chief Financial Officer on September 21st and is with us today for her first earnings call. Evelyn carries over 20 years of senior financial leadership experience spanning both public and private companies. Most recently, she served as CFO of Staples Canada, and before that held CFO positions at Enercare, Key REIT, and United Purchasing Group of Canada. Across her career, she's had responsibility for financial reporting, financing, treasury, investor engagement, and capital allocation, and she's closed over 50 acquisitions and divestitures. Evelyn also knows WELL well. For more than the past year she served on the Wellstar board, where she helped guide Wellstar through the process of going public. She came into this role with firsthand knowledge of our strategy, governance, and culture. Welcome, Evelyn. Let's now look at the quarter's highlights. Q3 was marked by continued execution on our key strategic priorities. We're pleased that we delivered 20% growth in normalized adjusted EBITDA compared with a year earlier. Our attention remains squarely on expanding the Canadian platform, extracting value from the companies within the WELL group, and making our balance sheet stronger. A few items stand out that we want to highlight today. First, WELL Canadian clinics hit a milestone of $100 million in annualized adjusted EBITDA run rate. For our Canadian clinics business alone, we had set a goal of reaching that run rate by the end of 2026, and we got there a quarter early. Second, Wellstar finished its standalone listing on the TSX Venture Exchange. At the time of listing, roughly $155 million of Wellstar redeemable preferred shares converted into Wellstar common equity, which took that liability off WELL's consolidated balance sheet. More on that will come later in the call. Third, we finished our first-ever offering of $150 million in senior unsecured bond notes. Those notes mature in 2031, which lengthens the schedule for our debt maturities, and we applied the money raised from the notes offering toward repaying our convertible debentures. Fourth, the Competition Bureau released a no-action letter on October 22nd, bringing its review of our purchase of a controlling stake in HEALWELL AI to a close; we worked alongside the Bureau during the entire process and value its involvement. Now for our outlook: we are revising our 2026 guidance, and we now anticipate revenue of roughly $1.58 billion, which sat at the low end of our guidance range. The main driver here is the timing of M&A, along with a purposeful slowdown in acquisition activity during the back half of the year, since our teams were concentrated on integrating the sizable deals closed earlier this year, including OID and UnionMD. Importantly, our profitability outlook is unchanged; we're still confident about delivering adjusted EBITDA solidly within the $185 million to $195 million range that we raised last quarter. Turning to the quarter itself. Before walking through the figures, a brief note on comparability. Q3 is our first quarter with no revenue deferral effects related to Circle Medical. For the current quarter, reported and normalized results are now the same. The gap in growth rates stems entirely from the prior-year period, which contained a $17.6 million net deferral impact from Circle Medical. Against that backdrop, here are our Q3 financial highlights: Revenue came in at $407.4 million, rising 12% year-over-year and 17% on a normalized basis. Adjusted EBITDA was $50.9 million, falling 15% year-over-year as reported, yet climbing 20% normalized, again excluding those deferred revenues. Adjusted EBITDA attributable to WELL shareholders totaled $34.8 million, down 19% as reported, but up 13% normalized. Adjusted gross profit reached $177.8 million, an increase of 7% year-over-year, or 20% normalized. Adjusted gross margin stood at 43.7%, 180 basis points lower as reported, but 100 basis points higher normalized. The reported decrease mirrors prior-year deferral recognition, which came with almost no associated cost and thus inflated last year's margin; normalized, margin expansion keeps being driven by revenue mix shifting toward higher-margin businesses, including Wellstar, diagnostics, and executive and longevity health. Adjusted net income was $27.3 million, down 33% as reported, or down 15% normalized. That normalized decrease mainly reflects a one-time gain on disposal in the prior-year period, plus legal and other costs. Evelyn will cover the financials in greater detail later on the call. One key takeaway: normalized, adjusted EBITDA grew faster than revenue, reflecting our revenue mix continuing to shift toward higher-margin businesses. Since deferral effects are no longer a factor, our reported figures will from here on mirror how the business actually performs. Moving on to operational metrics. HEALWELL and Wellstar are not included on this slide because each is publicly listed and will address its own metrics. The operational metrics shown here pertain to our clinical operations across Canada and the United States. The $100 million annualized adjusted EBITDA run rate reached in Canadian clinics is a direct result of the strength of these underlying operating metrics. Within Canada, WELL's clinical network now comprises more than 3,400 providers, including over 1,500 physicians. Canadian patient visits reached 1.3 million during the quarter, a 20% rise compared with the prior year. Organic growth accounted for 6%, consisting of 1.9% from same-clinic performance and 4.1% from absorptions. On an annualized basis, that works out to 5.1 million patient visits in Canada by itself, excluding asynchronous digital interactions. We finished the quarter running 179 physical facilities in Canada. A single facility may contain several clinics, and each clinic delivers a different healthcare service. I'll come back to that point when I talk about our clinical count. In the US, more than 1,500 providers made up our clinical network, including over 500 physicians. US patient services recorded approximately 665,000 visits, up 1% from the previous quarter, with organic growth of 4%, and CRH continues to serve 152 ambulatory surgery centers and GI clinics. Across the US and Canada combined, WELL has close to 5,000 providers who deliver more than 8 million patient visits each year, and that figure excludes asynchronous interactions. For a few quarters now, we've been profiling metrics that demonstrate WELL's favorable influence on Canadian healthcare, and we'd like to keep doing so. From the current quarter, here are four illustrations. To begin, patients keep reporting that they appreciate the tech-enabled way we deliver care. During Q3, WELL clinics posted a Net Promoter Score of 84, while the industry average stood at 34. Next, Wellstar handled over 520,000 e-referrals during the quarter, and every one of those links a patient to specialist care faster, with less administrative work for providers. Third, at WELL clinics during Q3, HEALWELL went through over 62,000 patient records for the purpose of disease detection, which assists our clinicians in identifying patients who could benefit from earlier intervention. Fourth, in collaboration with HEALWELL, we passed the 100,000 WELL Trust consent milestone in Q3. By October 31st, we have collected more than 120,000 WELL Trust consents so far.
WELL Trust, you should know, offers patients a way to take part in research and data-driven care where consent comes first. The vision behind WELL is to serve as the operating system that underpins outpatient healthcare at scale, supporting a more modern Canadian healthcare system. During the previous quarter, I spoke about OneWELL, the integrated offering that spans the WELL group of companies. In Canada, OneWELL comprises over 300 clinics and more than 1,500 physicians, handling 5.6 million visits on an annualized basis. That includes the largest diagnostic group in the country, which has upwards of 85 locations. No other integrated platform nationwide combines large-scale care delivery, the technology required to operate and continuously enhance that delivery, and an intelligence layer that turns the resulting data into improved care and better tools for providers. Simply put: clinics providing care, technology operating it, and AI making it smarter. Wellstar's tech covers intake, scheduling, billing, security, and clinical decision support with a person always in the loop for those providers, while HEALWELL's clinical AI pinpoints patients and assists health systems via data interoperability solutions; through this integrated stack, provincial health systems can work with one partner across the entire continuum of care instead of a patchwork of point solutions. To our knowledge, no one else in the country can deliver this impressive set of capabilities inside a single group. I'll now move to our public sector opportunity. Every provincial government nationwide shares a core set of goals: faster access to care, getting primary care for the more than 6.5 million Canadians without a family doctor, shortening waits for specialist referral and consultation, and bringing down system costs with digital tools. Those goals match up squarely with the structural pressures we described last quarter, and in our view OneWELL was designed for exactly this point in time. Our approach is building momentum. At present we are in active discussions at the federal level and with several provincial health authorities, chasing opportunities worth well above $100 million in contract value. To be clear, these are pipeline opportunities we are actively pursuing, not contracted revenue. Timelines and results in public-sector procurement can't be predicted with certainty, and we'll continue to keep investors informed as those opportunities move forward. There are three reasons we think OneWELL is strongly positioned. First, we bring together care and technology. Our clinical network — which takes in the biggest physician network in the country — lets us prove our solutions in our own clinics before they get deployed across other health systems. Second, we're Canadian and sovereign. Patient data remains in Canada, a factor that matters more and more to provincial health authorities and governments. Third, our platform is both interoperable and modular. It can scale from one clinic all the way to a whole province, consistent with Bill S-5, the Connected Care for Canadians Act, and with the pan-Canadian interoperability roadmap. All of that, taken together, makes WELL a partner provincial health systems can rely on for the long haul. Let me move on to how our capital is structured. In July, WELL completed its inaugural sale of senior unsecured notes — $150 million carrying 6.875%, coming due in 2031, and ranking pari passu with our other senior unsecured indebtedness. What was the reason behind it? The rationale was simple: ahead of a maturity we already saw on the horizon, we aimed to fine-tune the capital structure. We carried $70 million of convertible debentures coming due at year-end, and the bond proceeds have now been used to repay them. Whatever remains is directed to general corporate purposes. The upshot is a cleaner balance sheet, a maturity runway that now stretches to 2031, and more room to keep fueling our growth in Canada. I'd like to underscore what this offering really means. Not many Canadian growth companies get access to the senior unsecured bond market, and the oversubscription on this deal speaks to investors' confidence in how high-quality and durable our cash flows are. It hands WELL a fresh capital source that we can tap again as we expand. The Wellstar listing marks the second big move we made this year to reinforce WELL's capital structure. As I said earlier, Wellstar started trading on the TSX Venture Exchange on October 1st, under the ticker WSTR. The most immediate effect is deleveraging on our balance sheet. Roughly $155 million of Wellstar redeemable preferred shares turned into Wellstar subordinate voting shares when it listed, which takes that liability off WELL's consolidated balance sheet. Combined with the bond offering, these two deals have substantially simplified our capital structure and given us more financial flexibility. The listing also creates value by establishing a public market valuation for Wellstar, based on its recent share price. Wellstar carries a market capitalization of about $469 million, and WELL stays its majority long-term controlling shareholder. Wellstar itself is well-capitalized, holding $93 million in cash and no debt as of September 30th. Wellstar is continuing to show remarkable growth as well: in Q3, revenue climbed 33% compared with the same period a year earlier, while annual recurring revenue reached $83.7 million, up 27% year-over-year. Now let's turn our attention to WELL's Canadian clinics, covering both multidisciplinary medical clinics—including primary and specialty care—and diagnostic imaging clinics. As I mentioned at the beginning of this call, this business has reached a $100 million milestone in annualized adjusted EBITDA run rate, one quarter sooner than our year-end goal. This business has compounded steadily. Beginning in 2021, Canadian clinic revenue has compounded annually at 47%, while adjusted EBITDA has grown at a 44% CAGR; this has come from a combination of acquisitions that add value, organic expansion, and continued progress on our clinic transformation program. Ahead of discussing our clinic count, I'd like to flag a reporting change. As of this quarter, we have revised what qualifies as a clinic and restated prior-period clinic counts using that same basis, so the numbers shown on the slide can be compared across periods. The revised definition treats a clinic as a distinct healthcare service identified by its brand, business, or P&L, its care team, or its EMR. A single physical location can contain several clinics—say, a primary care clinic plus a diagnostic or specialty clinic at the same site—and we count each one separately. By that method, as of September 30th, WELL ran 302 clinics in 179 physical facilities, versus 128 clinics when 2022 began. Clinics affiliated with WELL are excluded from this figure. Let's now turn to the record Q3 results from our Canadian clinics, which truly are the engine driving everything I've described up to this point. Revenue from Canadian clinics rose 49% to $164.9 million during the quarter. Crucially, organic growth stemming from same-clinic sales growth came in at 12%. We continue to see persistently elevated organic growth in this business, powered by provider productivity, the shifting mix toward diagnostic and procedural care, and the clinic transformation program. Adjusted EBITDA climbed at an even quicker pace, rising 82% to $25.7 million—about $100 million on an annualized basis—and that is the milestone I mentioned earlier. The adjusted EBITDA margin stood at 15.6%, an increase of roughly 280 basis points versus a year ago. That expansion mirrors the mix shift toward higher-margin services along with the operating leverage that comes from running a scaled network. I'd like to dwell on this for a moment, since it offers the clearest proof that our capital allocation strategy is delivering results.
Our capital has been going into Canadian clinics, and that is producing revenue growth, organic growth, and margin expansion simultaneously; that is the reason it stays our main target for incremental capital. Now on productivity throughout our Canadian clinics network, this slide looks at the third quarter of each of the last three years. As a reminder, a patient visit means a completed encounter with a billable provider, whether in-person or virtual, and it does not include e-consults or asynchronous interactions. Visits in our Canadian clinic network came to 1.29 million in Q3, a rise of 20% from 1.08 million, and up from 780,000 two years earlier. Billable providers came to 2,400, a gain of 17% versus a year ago, and up from 1,769 in Q3 2024. Visits per billable provider climbed to roughly 534, an increase of 3% from roughly 520 a year ago, and 18% from roughly 441 two years ago. Across the last two years, visits have grown consistently faster than our provider count, meaning every WELL provider is seeing more patients. AI scribing, digital intake, and our wider clinical transformation program are still the main drivers, giving our providers more time with patients and less time on administration. Growth in visits per provider eased to 3% this quarter, which largely reflects mix. The acquisitions we closed in the first half brought a large number of billable providers into the base mid-year, and the visit profile of a newly acquired diagnostic or specialty provider is different from that of an established primary care provider. Inside our more mature clinics, productivity kept improving; now on to Canadian clinic M&A. This quarter, we're showing activity on a year-to-date basis, since after a very busy first half, Q3 was intentionally a quieter quarter while we focused our teams on integrating the businesses already acquired, most notably OID and UnionMD, two of the larger and more strategic acquisitions in our history. Getting those integrations right matters greatly for delivering the returns we expect from them. Our year-to-date activity is well ahead of last year. Year-to-date in 2026, we've closed seven transactions adding 27 clinics, and approximately $102 million in annual revenue and 203 providers. That compares with 12 transactions in the same period of 2025, which added 19 clinics and approximately $67 million in annual revenue and 198 providers; put another way, we've added more than 50% more annual revenue this year through fewer, larger transactions with nearly the same number of providers; that reflects the more selective approach to capital allocation we discussed last quarter, with an emphasis on scale and higher-margin areas such as diagnostics and procedural health. Our pipeline of Canadian clinic opportunities now stands at $390 million in total revenue across more than 20 targets engaged, representing over 100 clinics. This includes deals under LOI and in the pre-LOI stage, but excludes the Wellstar and HEALWELL pipelines. With a stronger balance sheet and the OID and Union integrations progressing well, we're in a good position to return to a more normal cadence of acquisitions, supplemented by a regular flow of bolt-on deals, while staying disciplined and centered on opportunities with higher margins. Now, an update on the strategic alternatives processes for our US care delivery assets: CRH Medical, Wisp, and Circle Medical; these processes are considerably further along than at the time of our last discussion. Back in September, we outlined a wide set of interested parties. We're happy to say now that two of the three processes have moved into a more advanced phase with focused counterparties, and we're driving toward definitive outcomes. We won't discuss specific parties, structures, terms, or timing until there is something binding to announce, and once there is, we'll disclose it promptly. One more point on how we're approaching this: securing the right partner and certainty of execution for these businesses is important, along with the right commercial arrangements. Our decision-making here is multi-pronged by nature. Also, the objective remains unchanged: it is to unlock capital, simplify the company, and concentrate our focus and resources on Canada, where our clinics business is delivering the results we discussed earlier. Turning briefly to how these businesses performed in the quarter, we'll begin with Wisp. Wisp brought in revenue of $29 million in Q3, versus $30.3 million in Q3 last year. Adjusted EBITDA came to $3.2 million, rising approximately 146% from $1.3 million a year ago, which made Q3 Wisp's strongest quarter of the year on an adjusted EBITDA basis, and overall the strongest EBITDA performance in years. That mirrors the emphasis on margins and cost management that Wisp's leadership implemented earlier this year. Circle Medical brought in revenue of $25.2 million, versus $42 million in Q3 last year. The prior-year period included $17.6 million of revenue deferral impact; on a normalized basis, revenue rose by 3%, and adjusted EBITDA was $2.2 million, versus $4.8 million a year ago on a normalized basis, reflecting higher expenses to support the company's team, including compliance, as well as greater marketing costs. CRH and provider staffing together generated revenue of $126 million, flat year-over-year, with growth in anesthesia offset by lower provider staffing revenue. Adjusted EBITDA for the quarter was $23.7 million, up 4.5%. With that, I'll hand the call to Evelyn to discuss the Q3 financial results. Evelyn.
Thank you, Hamed, and good afternoon to all of you. It's a pleasure to be part of WELL at such a pivotal point in the company's journey. During the last few weeks, I've had the chance to spend time with our teams and operating businesses, and I've come to appreciate just how large the platform is and what opportunities await us. I'm eager to collaborate with Hamed and the wider team, and to get to know many of you over the months ahead. With that, I'll move on to our financial results for the third quarter. Let's begin on slide 17, which shows the bridge from Q3 2025 revenue to our results for the current quarter. WELL posted $407.4 million in revenue for Q3 2026, compared with $364.6 million in the same quarter last year — reported growth of 12%. However, last year's figure included $17.6 million related to the Circle Medical revenue deferrals. If you remove that, normalized Q3 2025 revenue was $347 million. When we compare this year's $407.4 million to last year's normalized $347 million, that's $60.4 million of growth, or 17%, consisting of $54.5 million from Canadian clinics and $5.9 million from the rest of our businesses. That really highlights how the Canadian clinics are the main growth driver for the company. One key point for Q3 2026: Circle Medical revenue deferrals had zero effect, so reported and normalized revenues are now identical at $407.4 million. On slide 18, we show a similar bridge for adjusted EBITDA. WELL's adjusted EBITDA for Q3 2026 came in at $50.9 million, compared with $59.9 million in the year-earlier quarter — a reported drop of 15%. But as we noted on the previous slide, last year's figure included $17.6 million related to the Circle Medical revenue deferrals. Strip that out, and normalized adjusted EBITDA for Q3 2025 was about $42.3 million. When you put this year's adjusted EBITDA of $50.9 million next to last year's normalized adjusted EBITDA of $42.3 million, that works out to roughly $8.6 million of net growth, or 20%. The bridge makes clear that Canadian clinics drove much of that increase, contributing $11.6 million to adjusted EBITDA and thereby partially offsetting the adjusted EBITDA loss coming from corporate headquarter costs and other business units. The adjusted EBITDA strength in the Canadian clinics reflects contributions from acquisitions, including OID and UnionMD, as well as the ongoing shift toward higher-margin services. Notably, Q3 2026 saw no Circle Medical deferral impact, which means our reported and normalized adjusted EBITDA now match at $50.9 million. The main point here is that adjusted EBITDA, on a normalized basis, increased at a quicker pace than revenue did — and that speaks to how our business mix keeps shifting toward operations with higher margins. If you turn to slide 19, you'll see the reconciliation from the net loss we reported to adjusted net income for the quarter. WELL recorded a net loss of $135.5 million in Q3 2026, while adjusted net income was $27.3 million. The sizable difference between those two numbers stems from several accounting charges taken during the quarter, including non-cash impairments and transaction-related accounting connected to Wellstar. Let me go through two of the larger items. The first is our impairment charges. In our annual impairment test, which wrapped up on September 30th, we recorded impairment charges of about $67.5 million in total, including a one-time $39.8 million impairment tied to HEALWELL. These are non-cash charges, so they don't affect operating cash flow for the quarter. I think it's worth giving some context on HEALWELL, particularly since the charge is so large. In April 2025, when WELL gained control of HEALWELL, accounting rules meant we had to revalue the investment we already held using HEALWELL's share price at that point, which was $1.47 per share. That led to a substantial increase in the accounting value assigned to our investment and fed into the intangible assets and goodwill we recognized on our balance sheet. This quarter we took a $39.8 million impairment, which mirrors a decrease in that goodwill. Even with that charge recognized, the worth assigned to our investment still sits measurably higher than what we originally paid to invest. During our yearly impairment review, we likewise evaluated and booked impairment charges against the carrying values of Cycura and BioPharma Services Inc., or BPSI, both part of WELL Research. In both of those latter two instances, the charge mirrors an intentional shift in where those businesses are headed strategically. Looking ahead, WELL Research will concentrate more on our higher-margin site management organization, or SMO, and less on lower-margin contract research organization, or CRO, operations. Right now, SMO is a modest but profitable operation, and that's the area where we'll be directing additional resources as we work toward bringing a number of WELL Clinic sites online throughout Canada as clinical research locations. That falls under the WELL Research initiative, which draws most directly on both our clinic network and our WELL Trust consent platform. Turning to Cycura, that business has traditionally been weighted toward one-time security hardware sales, a large portion of which came over through the Source 44 acquisition, along with irregular project revenue from things like threat risk assessments. As the reseller model has played out, hardware revenue has fallen considerably, and it was that drop that led to the impairment and to the shift in strategy. Our company today centers on a data protection platform built around recurring revenue—a smaller revenue base at present, yet one that is more durable and carries a higher margin. In each instance, we view these transitions as the correct path given the long-term orientation of these businesses, and we have brought in new leadership to support them. We also recorded an impairment on Adracare, a virtual care technology business serving allied health providers that we acquired during the pandemic and that has not reached profitability. Adracare was not part of Wellstar at the time of the listing, since Wellstar is focused on technology for physicians, and after the quarter ended we closed the sale of that business on November 1st. Exiting Adracare removes a drag from operating losses and aligns with our broader effort to streamline the portfolio and steer resources toward strategic priorities. Next, the accounting associated with the Wellstar deal. During the quarter, we booked accounting charges stemming from Wellstar's reverse takeover transaction—covering the listing expense and interest accretion, as well as remeasurement expense on its redeemable preferred shares; those charges contributed substantially to our reported net loss, but they are not indicative of Wellstar's underlying operating performance. The transaction was completed in the quarter, and Wellstar started public trading on October 1st. Once you account for those and the other adjustments laid out in the bridge, WELL's adjusted net income for the quarter came to $27.3 million, which works out to adjusted EPS of $0.11. On slide 20, we shift from earnings over to cash flow. The slide walks from our adjusted EBITDA of $50.9 million down to adjusted free cash flow of $25.6 million, and from there to operating adjusted free cash flow attributable to shareholders of $13.3 million — versus $15.1 million a year earlier. Our underlying adjusted EBITDA was up 20% once you normalize for last year's Circle Medical deferral, but that improvement did not translate fully into greater free cash flow in the quarter. Three primary elements were in play. To start, we continued allocating capital toward improving the clinical portfolio in Canada, and that backs long-term expansion and earnings for those businesses. Next, our cash tax outlays rose this quarter, driven in part by the effect of deals we closed during the past twelve months; even so, we took encouragement from recent federal budget proposals regarding the ability to shift tax losses among wholly owned Canadian corporations. Those proposals require additional work before they are finalized, yet they might create further chances to streamline our tax structure and reduce cash taxes throughout our Canadian operations. Third, interest payments came in higher, which mirrors the larger credit facility we drew on to fund strategic investments aimed at strengthening our clinical portfolio through deals such as ECC, OID, and UnionMD. There is an interest expense attached to the bond offering that Hamed walked through, yet it provides fixed-rate financing with longer maturities and more predictability regarding what our borrowings will cost. Going forward, better cash conversion stays a key priority for us; our attention is on disciplined capital investment, keeping financing costs in check, streamlining and expanding automation across back-office operations, and converting a greater share of our earnings into free cash flow attributable to WELL shareholders. All in all, I think WELL is well-positioned for the next phase of growth. Our capital structure is solid, we have a strong base of established businesses, and there are significant opportunities in front of us; so with that, I'll hand the call back to Hamed for our outlook.
Thanks, Evelyn. We anticipate that the company's robust operational results will carry on through the rest of 2026 and on into 2027, and that management will stay intently focused on fine-tuning operations to drive organic growth and profitability. Four main catalysts deserve attention: First, the 2026 guidance we have just updated — revenue of roughly $1.58 billion, which works out to 16% normalized growth over 2025 once you strip out Circle Medical and CRH Medical Corporation one-time events from both fiscal 2026 and 2025, alongside adjusted EBITDA of $185 million to $195 million, equal to normalized growth of 13% to 19%. Keep in mind this guidance captures only acquisitions announced so far, and by September 30th, 2026, we had recognized the entire $17.6 million of Circle Medical deferrals that the guidance contemplates. Second, during the prior quarter we established a target for WELL Canada — defined so as to include WELL Clinics and Wellstar — of hitting a $1 billion revenue run rate before 2028 ends. With Wellstar now public, we have revised the nomenclature and reconfirmed that target. Third, apart from the Circle Medical deferrals, we anticipate carrying on our multi-year pattern of posting adjusted EBITDA annual growth above 10%, counting both acquisitions and organic growth but leaving out any divestitures. Fourth, we plan to set up OneWELL as a partner to provincial and federal health systems and to start converting the public sector pipeline we outlined previously. Our dedication to disciplined capital allocation is unchanged, and our Canadian clinic program stands as the main destination for incremental capital. That priority is the core reason we keep evaluating strategic alternatives for our US care delivery assets. Before wrapping up, a note on the impairments. The biggest one, tied to HEALWELL, is an accounting consequence of the value we were obliged to assign upon taking control last year. As Evelyn laid out, we are still ahead of our original investment. It helps to frame that in cash terms: our total cash outlay to build our equity position in HEALWELL came to about $13.9 million, while the rest of our stake arose from vending Intrahealth into HEALWELL two years ago in return for shares. As of today, we hold roughly 97 million HEALWELL shares, worth approximately $64.2 million at current prices. Although the accounting value has declined, the position itself is still comfortably above the cash and in-kind value we contributed. The other impairments represent the accounting effect of our strategic choice to leave non-core operations and steer Cycura and WELL Research toward businesses with higher margins and recurring revenue. In closing, Q3 brought several milestones, and I think the most notable were our Canadian clinics business hitting the $100 million annualized adjusted EBITDA run rate milestone ahead of our end-of-year target, on 49% revenue growth and 82% EBITDA growth year over year; Wellstar finishing its standalone listing, which removed about $155 million of preferred share liabilities from our balance sheet; and, through our inaugural bond offering, extending our maturity profile and repaying our convertible debentures. After the quarter ended, the Competition Bureau issued a no-action letter, which concluded its review of our acquisition of HEALWELL. Taken together, these accomplishments leave us with a stronger and simpler balance sheet, clearly focused on expanding our Canadian business; that is the reason we stay confident about meeting our adjusted EBITDA guidance for 2026. In closing, I want to thank our board of directors, the leadership teams throughout all our operating subsidiaries, including the teams at Wellstar and HEALWELL, and most of all, a big thank-you to our healthcare practitioners and frontline workers, who make a difference in our patients' lives each day. Thank you as well to our shareholders, investors, and the analysts who cover us, for your continued support and encouragement. Operator, we are now ready to take questions.
Thank you so much, and well done on how the clinics have performed; that's really encouraging to see.
Thanks, Rob. I appreciate it.
Regarding the clinics, could we go a bit deeper into that pipeline — the 20 targets and the $390 million in revenues? Can you give us a feel for absorptions? Are they clustered together? Do you expect them to be competitive situations?
Thanks, Rob. What I'd say is the mix really hasn't shifted much, since we've taken a very deliberate stance that we want to concentrate on higher-margin opportunities — especially diagnostics and even some of our private longevity and executive health offerings. I'd say there's a solid mix across all the different areas we focus on. There was a period when our attention was heavily on primary care and absorptions. There are certainly absorptions we're tracking, but I'd describe it as a very deliberate emphasis on engaging more in some of those higher-margin areas where you've seen us operate.
Good. Hearing you mention earlier on this call that executive and longevity are boosting margins was encouraging. Are they achieving greater scale and better margins?
Yes, definitely. I'd say our executive and longevity business is now beginning to be a genuine driver of the growth and results that are starting to show, even though we don't disclose those specific segments; at some point, I believe we can provide a bit more financial detail on that. I'd say it is certainly a growing, double-digit contributor to the medical clinic segment as a whole.
All right. Thanks.
Hello, and thank you so much for that question, plus congratulations on the results. Evelyn, good to have you on the call. My question concerns Canadian clinics, clearly the standout performer this quarter. I wanted to dig into the numbers: same-clinic sales rose 12% against 6% organic patient visit growth. I noticed some mention in the filings about reimbursement changes. Could you basically reconcile that gap between same-clinic sales and organic patient visit growth?
Sure thing, Michael. Thanks for asking. Yes, we did have some retro reimbursement that added to the quarter, and these sorts of impacts do occur from time to time. Keep in mind that organic growth remained fairly elevated even excluding the retro. I believe we landed at just under 10% same-clinic sales growth across clinics overall. That was still quite a strong result.
Okay, that's excellent—very clear. So, given that your Canadian clinics are now hitting $100 million in annualized adjusted EBITDA earlier than expected, where do you think we should be looking? I mean, what are the biggest chances for additional margin expansion in 2027, considering how strong the levels already are?
We think margin expansion can keep occurring as we take advantage of our clinic transformation program. Our team hasn't yet finished rolling out all of their newest opportunities to modernize, digitize, and improve. At this point it's really about AI-enabling our physicians. Wellstar and HEALWELL—especially Wellstar's provider-facing technologies—are ones we're collaborating on and deploying very heavily. I'd say we expect margin expansion from the clinic transformation program to keep happening steadily over time. I'd also mention that our deliberate emphasis on mix shift, along with some of that robust organic growth you heard about earlier, is coming from our diagnostics business. When we make acquisitions—this even occurred before we purchased the MyHealth platform years ago—we've observed that the team was quite skilled, quite capable of driving meaningful organic growth right after an acquisition, thanks to all the opportunities they identified when they acquired the clinics; that's something we've kept seeing. I think organic growth will oscillate somewhat depending on our M&A, because of the opportunities for revenue acceleration that come from that portfolio. Broadly, this is a major objective for us. Another point I'd make is that, as the SMO Evelyn discussed, there's a focus on SMO as part of WELL Research. That's a small business today, but looking ahead years, we really expect that as we begin carrying out site management activities from a clinical trial perspective—first of all, that's great for providers. Providers are seeking ways to get deeper within our network and have more chances to also grow and also benefit financially. With this clinic infrastructure and the provider base we have, this is a very attractive, high-margin opportunity and really lets us kind of pharma-activate our clinical network. We believe that can add hundreds of basis points overall to our clinical framework over time.
And just to add a quick follow-up question there, what margins do you figure we should be expecting from the SMO activity?
Once more, it's a quite small business at present—we're really talking about what's ahead. SMO businesses generally tend to run at operating margins quite a bit above 20%. That's the objective for that business, and it can go even higher than that, in the sense of being over 25%, 30%, and so on and so forth. I think deploying it will take a while, and getting the proper infrastructure set up. Look, our long-term objective across clinics and research combined is to surpass 20% operating margins for the whole network, and that would take in some of your lower-margin, more plain vanilla medical clinics too. Plenty of strategies and emphasis on pushing margins upward as time goes on.
Thanks a lot, Hamed. I'll hand things over.
Hey, everyone. I've got a question about the guidance. Looking at the revenue guidance, it kind of suggests revenue could be roughly flat or perhaps a bit lower compared with Q3 when we get to Q4, and I believe Q4 has usually been a seasonally stronger quarter. I'm curious how much of that comes from, or how much is tied to, the US businesses, since there was a mention of some possible softness, I think, in Q4?
David, good question. What we're really talking about here is — even if you look at where things stand right now, and extend that using our usual revenue pattern — we still anticipate a strong showing from CRH anesthesia. It's really about the staffing; we had, let's say, two staffing businesses. One goes by the name Radar. You might recall the other one is Harmony. Harmony keeps delivering strong, double-digit growth. Radar had a harder year, with some churn during this year. That's really what's pulling some of our revenue down; it has nothing to do with Canada, and nothing to do with our core anesthesia operations, which had a fantastic year. That's really most of what's behind some of that weaker revenue. As we mentioned, we expect adjusted EBITDA — and we raised guidance last year — to remain really strong within our range.
Oh, that helps. Thanks, Hamed. So just one further question about Wellstar. If you look at their revenue, about mid-single digits come from WELL. Could you discuss what you're doing to drive greater uptake of Wellstar's solutions across your clinic base?
Yes. Great question. This is a major subject of discussion, since we're quite excited about the innovation at Wellstar. Wellstar, in my view, is building a truly fantastic platform. The industry is genuinely beginning to shift away from point solutions. Having an AI scribe is nice, but what lies ahead is defined by something like a continuous platform and workflows that function well together, rather than just those point solutions. Wellstar's Nexus platform accomplishes that. We have pretty solid plans to adopt Nexus in its entirety. Naturally, we don't use the WELL EMR across all our locations. That's not possible, given that we're an acquirer and we do acquire clinics that don't use WELL's EMR. More and more, our focus is to, again, bring some of those same clinical transformation features to those other EMRs as well. Where we can, shift some of them across. That is certainly part of our playbook. Where possible, we want to make use of Wellstar. We'd anticipate seeing WELL grow as a customer, which is basically the punchline.
How long do you figure it might be before what you contribute to Wellstar's revenue reaches the double digits? And how fast are you rolling this out across your clinic base?
I'm not certain about double digits, since they're growing outside of WELL as well. On an absolute basis, I believe we'll keep growing as a customer. Wellstar is doing really well with the provincial health authorities too, and their solutions are becoming really sought after clear across the country; we expect they'll keep building momentum outside our network. I think that even holding our current share of their revenues will require pretty significant growth from us, and on an absolute basis, which we will be doing.
That's excellent. Thank you.
Good afternoon, and thanks for taking my call. The opening remarks mentioned the Canadian federal budget, and from what we understand there's a new deduction mechanism for medical equipment; that covers x-ray and ultrasound machines, but it sounds like it could reach a broad range of capex for Canadian physician clinics. My question is whether there's a way to quantify this impact in terms of tax savings or on the returns for the Canadian patient services segment, unless it's too early to assess?
Thanks, Justin. Evelyn, perhaps I'll ask you to weigh in on this one.
I’m glad to jump in on that. Justin, as you suggested, I believe it’s a bit too soon to say anything about it, simply because the specifics haven’t come out yet. As soon as they do, we’ll be glad to give an update on that front.
Great. I'd imagine this applies mostly to MyHealth in the diagnostic segment?
It would, yes, though as I say, the devil's in the details, and we'll have to wait for those details to come out.
Got it. I’m looking forward to hearing the specifics. Thanks.
You’re welcome.
Justin, as Evelyn pointed out during our excellent presentation, there are also a few tax proposals that are quite interesting and could have a significant impact. We share your enthusiasm for the federal budget. We'll keep all of you updated.
Sorry about that. Hey, everyone. Evelyn, welcome. The first thing I want to ask is for you. I think you mentioned in your prepared remarks that cash conversion is a priority. I noticed that adjusted free cash flow to shareholders came in at roughly $13.3 million, compared with $15.1 million a year ago, and that's even with the 20% growth in normalized EBITDA. So I'm curious: how should we be thinking about normalized capex, cash interest, and cash taxes as we head into 2027?
That's a really good question. We'll likely keep investing in much the same way we've done historically. I'm somewhat hesitant to offer guidance because the business may be changing. When it comes to the Canadian clinic side, my guess is we'll invest up to the same level we have in the past. Hamed, I don't know if you'd like to add anything?
No, I think you said it well. Yep, nothing to add.
All right. So, if I could, just one quick follow-up question regarding that public sector pipeline of over $100 million. When do you expect the first awards to come through, and once OneWELL does secure a win, how would revenue and margins be divided among WELL, Wellstar, and HEALWELL?
That's a really good question. Look, we've now established a public sector team led by Dr. Andrew Bond, and that team functions as a shared resource; it's partly being funded not only by WELL Health but also by subsidiaries such as Wellstar. There are charge-out methodologies and intercompany arrangements in place there. Say it's an RFP or a scenario that has multiple components — and that's precisely the whole concept behind OneWELL, which is that a public sector opportunity could very much involve componentry tied to WELL Health Clinics, Wellstar, and/or HEALWELL all within a single engagement; we would take away that complexity on the public sector side and have them deal with one group, and then we'll handle the complexity and abstract all the charge-outs and project management elements behind that. Honestly, we believe that will prove very useful for the public sector groups. That's the way we would approach it.
All right.
I'd simply mention that the teams at Wellstar and HEALWELL will keep pursuing their own public-sector deals. Not all public-sector involvement is going to happen through this route. It's only in cases where our approach is more integrated and cohesive that we'll take that path. The same applies to WELL Clinics. WELL Clinics likewise has the ability to work with the public sector on its own, without HEALWELL and Wellstar. This is a fairly dynamic environment.
Certainly. That helps. Thanks.
Many thanks, operator, and many thanks to all of you for being with us on today's call. Our thanks go to Evelyn for being with us on this first call of ours; having her aboard has been great. We're very much looking forward to a really strong close to the year and to seeing all of you in March of 2027, when we'll go through our full-year results together. Thank you, and if we don't talk before then, enjoy a wonderful holiday.
Thank you. That brings us to the end of today's conference call. We appreciate your participation, and we ask that you please disconnect your lines.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete WELL Health Technologies Corp. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to WELL Health Technologies Corp. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.